Evidence map›Paper›PMID 40815535›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2025

Brief Report: Undetectable HIV-1 Viral Load Among Virally Suppressed People Living With HIV: Implications for Undetectable Equals Untransmittable (U=U) in Resource-Limited Settings Using Dried Spot Testing.

Gregory C Chang, Trista Bingham, Hetal K Patel, Elisabeth Mungai, Katrina Sleeman, Irene Benech, Dejana Selenic, Melissa Metz, Yen T Duong, Suzue Saito and 23 more

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Gregory C ChangDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0003-1922-025
Trista BinghamDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0002-1949-5133
Hetal K PatelDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.
Elisabeth MungaiDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0003-3077-8270
Katrina SleemanDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0003-2008-8540
Irene BenechDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0001-5444-9880
Dejana SelenicDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0003-2160-2943
Melissa MetzICAP at Columbia University, New York, NY.
Yen T DuongICAP at Columbia University, New York, NY.
Suzue SaitoICAP at Columbia University, New York, NY.
Judith ShangDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.
Emily K DokuboDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0002-1499-0151
Laura EnoDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0009-0009-1958-7175
Tsietso Mots'oaneMinistry of Health Lesotho, Maseru, Lesotho.
Caroline RyanDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.
Andrew AuldDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0001-5089-9163
Evelyn KimDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.
Alice MaidaDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0002-2317-2484
Optatus MalewoDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.
James M JumaMinistry of Health Tanzania, Dar es Salaam, Tanzania; and.
Anna Colletar AworDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.
Nzali KancheyaDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0002-5824-5428
Clement B NdongmoDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0003-0177-8458
Shirish BalachandraDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0002-4970-5939
Yimam GetanehDepartment of HIV and Tuberculosis, Ethiopia Public Health Institute, Addis Ababa, Ethiopia.
Sileshi LulsegedICAP at Columbia University, New York, NY.ORCID 0000-0001-6801-7034
Frehywot EshetuDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0001-8058-2044
Peter W YoungDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.
Daniel B WilliamsDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.
Christine WestDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.
Jessica JustmanICAP at Columbia University, New York, NY.ORCID 0000-0003-4704-3115
Bharat S ParekhDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.
Andrew C VoetschDivision of Global HIV and TB, Global Health Center, CDC, Atlanta, GA.ORCID 0000-0002-0783-1312

Funding

CGH CDC HHS U2G GH001226
6 · The paper itself

Abstract

backgroundThe Undetectable=Untransmittable (U=U) campaign, grounded in strong scientific evidence, affirms that people living with HIV (PLHIV) with an undetectable viral load (VL), defined as ≤50 copies per milliliter (c/mL) or <200 c/mL of HIV RNA, do not transmit HIV to sexual partners. In resource-limited settings, VL is commonly measured using dried blood spot (DBS) testing, which has a higher limit of detection (550-1000 c/mL). We report the proportion of PLHIV with VL <1000 c/mL who also had VL <200 c/mL and ≤50 c/mL to inform interpretation of DBS VL results under U=U.

methodsWe analyzed data from 13 cross-sectional nationally representative surveys (2015-2019), including PLHIV aged 15-59 years receiving antiretroviral therapy (ART) with valid plasma VL results. We estimated the proportion of participants with VL <200 c/mL and ≤50 c/mL among those with VL <1000 c/mL, overall and among those on ART ≥12 months using survey weights.

resultsAmong 16,533 PLHIV across 13 countries, 87.3% had VL <1000 c/mL. For PLHIV with VL <1000 c/mL, 95.4% had VL <200 c/mL and 84.9% had VL ≤50 c/mL. Among those on ART ≥12 months, 96.6% had VL <200 c/mL, and 87.4% had VL ≤50 c/mL.

conclusionMost PLHIV with VL <1000 c/mL had a VL <200 c/mL and ≤50 c/mL, indicating no risk of sexual HIV transmission. Our findings provide evidence that in settings relying on DBS VL testing, most PLHIV with VL <1000 c/mL likely fall below 200 c/mL or are undetectable based on the assay's lower limit of detection.

Indexed as

Dried Blood Spot TestingHIV-1HIV InfectionsViral LoadAdolescentAdultAnti-HIV AgentsCross-Sectional StudiesFemaleHumansMaleMiddle AgedResource-Limited SettingsYoung AdultAnti-HIV Agentsdried blood spot testingHIV infectionHIV transmissionplasmapreventionviral load

Identifiers

PMID40815535
PMCPMC13047505

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.